Blockchain Registration Transaction Record

Helus Pharma Names Michael Halstead CEO as Phase 3 Trials Advance

Helus Pharma appoints Michael Halstead as CEO, advancing Phase 3 trials for HLP003 in major depressive disorder. Learn about the new leadership and pipeline progress.

This leadership change is significant for investors and patients alike. Michael Halstead's proven track record in bringing a major psychiatric drug to market and navigating a high-profile acquisition could accelerate Helus Pharma's path to commercialization. With Phase 3 data expected in 2026, the appointment signals confidence in the company's pipeline and may influence investor sentiment. For patients with major depressive disorder, successful development of HLP003 could offer a new, potentially durable treatment option, addressing a critical unmet need in mental health.